Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location contact
Lorenzo Berra, MD
CONTACT
Maurizio F Cereda, MD
CONTACT
NCT Number: NCT07019987
Acute Hypoxemic Respiratory Failure (AHRF) is a condition in which injury to the lungs impairs the ability of the air sacs (alveoli) to ventilate and exchange oxygen. This impairment may be worsened in individuals with elevated body weight, particularly when fat tissue compresses the lungs and promotes alveolar collapse. The impact of body weight on lung function may be greater in individuals with upper-body fat distribution.
Two common interventions for AHRF-positive end-expiratory pressure (PEEP) and prone positioning-are used to improve lung ventilation. However, it is unclear whether these therapies are equally effective across different body weight categories and fat distributions.
This study will evaluate whether body weight and fat distribution affect patients' lung inflation responses to PEEP and prone positioning. Lung inflation will be assessed using electrical impedance tomography (EIT), a bedside imaging tool that maps lung ventilation, and esophageal manometry, which estimates lung compression through a thin catheter placed in the esophagus. Laboratory tests will also be used to measure markers of inflammation and AHRF severity and find correlations with fat distribution and responses to the tested treatments..
Patients with AHRF requiring mechanical ventilation will be enrolled across a range of body weights. Each participant will undergo combinations of two PEEP levels and two body positions (supine and prone) for 30 minutes each. At the end of the study procedures, clinical care will continue as determined by the treating team.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02114, United States
Lorenzo Berra, MD
CONTACT
Maurizio F Cereda, MD
CONTACT
This study investigates the relationship between body habitus and the physiological response to ventilatory interventions in patients with Acute Hypoxemic Respiratory Failure (AHRF). The primary objectives are to determine:
Adult patients with AHRF requiring invasive mechanical ventilation will be screened daily in the intensive care units at Massachusetts General Hospital. The study team will coordinate with clinical staff and patient surrogates to obtain informed consent. Enrollment is limited to the period required to perform study-specific procedures. No follow-up visits or post-discharge interventions are planned.
After consent, participants will be equipped with two adhesive EIT electrode belts, placed bilaterally on the thorax, to measure regional ventilation. A pressure and flow sensor will be placed in the breathing circuit at the proximal end of the endotracheal tube. An esophageal balloon catheter will be inserted nasally into the distal esophagus (approximately 35-40 cm) to measure intrathoracic pressure (ITP) via esophageal manometry, recorded through an auxiliary module on the EIT device.
Once all monitoring devices are in place, patients will be evaluated for adequate sedation and ventilator synchrony. Baseline data will be recorded during ventilation at the clinician-selected PEEP level (PEEP_CLIN), including EIT, airway pressure, flow, and ITP signals over 20 consecutive breaths.
Subsequently, a PEEP titration trial will be conducted to identify an individualized PEEP value (PEEP_TIT) that minimizes both alveolar collapse and overdistension, using EIT-based criteria. The patient will then be ventilated at PEEP_TIT for 30 minutes, after which all measurements will be repeated.
Following supine data collection, patients will be transitioned to the prone position using standard clinical protocols, with participation from ICU staff (physicians, nurses, and respiratory therapists) in accordance with institutional practice. Continuous monitoring (including pulse oximetry and arterial blood pressure) will be maintained throughout the repositioning.
After achieving the prone position, a recruitment maneuver will be performed to standardize lung volume history. The EIT belts will then be reconnected, and the patient will be allowed to stabilize for 30 minutes at PEEP_CLIN before measurements are repeated. A second PEEP titration trial will be performed to determine PEEP_TIT in the prone position, followed by another 30-minute stabilization period and repeat data acquisition.
Arterial blood samples (2 mL each) will be obtained at each PEEP level in both positions (four total, 8 mL cumulative) for gas exchange analysis. An additional 10 mL sample will be collected during supine ventilation at PEEP_CLIN for biomarker analysis. Biomarkers of inflammation (e.g., IL-6, TNF-α, C-reactive protein) and adipose tissue-related factors (e.g., adiponectin, leptin, resistin) will be measured.
After study procedures, participants will be returned to the supine position unless otherwise indicated by the clinical team. All subsequent clinical decisions regarding ventilator management or patient positioning will be made by the attending care team.
This study seeks to generate mechanistic insights into how excess body weight and fat distribution affect the physiologic response to standard ventilatory interventions in AHRF, with the goal of informing more individualized approaches to respiratory support.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
EIT will be used to guide individualized PEEP titration in mechanically ventilated patients with AHRF. Each subject will receive mechanical ventilation at two PEEP levels:
PEEP_CLIN (set by the treating clinician)
PEEP_TIT (identified using EIT to minimize alveolar collapse and overdistension)
Both levels will be maintained for 30 minutes in each body position, with continuous physiologic data collected during each phase.
Each subject will be ventilated in both the supine and prone positions. Positioning will follow institutional protocols and be coordinated with clinical staff to ensure safety. After supine assessments are completed, the patient will be transitioned to prone, followed by a recruitment maneuver to standardize lung volume history. The PEEP titration protocol will then be repeated in the prone position.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
The primary outcome will be the difference in driving pressure (inspiratory plateau pressure minus total PEEP, in cmH2O) in response to PEEP titration strategies and to prone position. Changes in driving pressure will be correlated with body mass index, and with measurements of thoracic, and abdominal circumference.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
Changes in EIT-derived measurements of regional ventilation with PEEP titration and prone positioning. EIT regional ventilation is measured as percentage of total ventilation in each examined lung region.
Time frame: Day 1
Age will be measured in years.
Time frame: Day 1
Body height will be measured in meters and will be aggregated with body weight to yield body mass index (BMI) in kg/m^2.
Time frame: Day 1
Body weight will be measured in kg and will be aggregated with height to yield body mass index (BMI) in kg/m^2
Time frame: Day 1
Thoracic circumference will be measured in cm using a tape ruler placed at nipple level.
Time frame: Day 1
Abdominal circumference will be measured in cm using a tape ruler at the level of the umbilicus.
Time frame: Day1
Hip circumference will be measured in cm using a tape ruler placed around the widest portion of the hips.
Time frame: Day 1
The medical record will be reviewed and the presence of the following coexisting conditions will be recorded:
Hypertension Diabetes Heart failure Liver disease Cancer
Time frame: First 24 hours since admission
APACHE II is a severity score (Crit Care Med. 1985 Oct;13(10):818-29.) that will result from the aggregation of the following variables obtained from the medical record on the day of the study:
age, temperature, mean arterial pressure, pH, heart rate, respiratory rate, plasma sodium, potassium, creatinine, presence of acute renal failure (yes/no), hematocrit, white blood cell count, Glasgow coma scale, and inspired fraction of oxygen (<50%, >=50%).
Time frame: Day 1
The etiology of AHRF will be recorded from the medical record as a binary variable (pulmonary vs. non pulmonary cause).
Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position
The PaO2 will be measured in mmHg in arterial blood samples.
Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position
The PaCO2 will be measured in mmHg in arterial blood samples.
Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position
The pH will be measured in arterial blood samples.
Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position
The plasma bicarbonate will be measured in mEq/l with an arterial blood sample.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
Plateau airway pressure will be measured in cmH2O during an inspiratory hold of the ventilator.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
Respiratory rate will be measured in breaths per minute during tidal ventilation.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
Peak inspiratory pressure will be measured in cmH2O at the end of a tidal breath by the ventilator.
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
PEEPt will be measured in cmH2O during an expiratory hold of the ventilator
Time frame: Day 1, after 30 minutes in each combination of PEEP and body position
Mean arterial blood pressure will be measured in mmHg through a preexisting arterial line and recorded by the clinical monitor.
Time frame: Day 1
We will calculate the Vasoactive-inotropic score (VIS). The VIS compares different vasoactive-inotropic drugs and doses among the patients. VIS = dopamine dose (mg/kg/min)+ dobutamine [mg/kg/min) +100 x epinephrine dose (mg/ kg/min) +50 x levosimendan dose [mg/kg/min) + 10 x milrinone dose [mg/kg/min)+ 10,000 x vasopressin [units/kg/min) + 100x norepinephrine dose [mg/kg/min) using the maximum dosing rates of vasoactive and inotropic medications. Ref: Koponen et al. British Journal of Anaesthesia, 122 (4): 428e436 (2019). This exploratory outcome plans to combine driving pressure and electrical impedance tomography with other markers (demographical, body metrics, clinical, biochemical, and inflammatory) to identify responses to PEEP and prone positioning.
Time frame: Day 1
The presence of the following life sustaining therapy on the day of the study (in addition to mechanical ventilation and vasoactive medications) will be recorded as binary variables (yes/no) from the medical record:
antibiotics, renal replacement therapy, and artificial nutrition.
Time frame: Day 1, once
IL-6 (ng/mL) is an inflammatory biomarker that will be measured in blood samples that will be collected on the day of the study.
Time frame: Day 1, once
CRP (mg/L) is an inflammatory biomarker that will be measured on a blood sample obtained on the day of the study.
Time frame: Day 1, once
Adiponectin (micrograms/mL) is a marker of adipose cell metabolic activity that will be measured in a blood sample obtained on the day of the study.
Time frame: Day 1, once
Leptin (ng/mL) is a parker of adipose metabolic and proinflammatory activity that will be measured on a blood sample on the day of the study
Time frame: Day 1, once
Resistin (ng/mL) is a marker of inflammatory activity secreted by adipose tissue, it will be measured in blood samples obtained on the day of the study.
Time frame: Day 1, once
TNF alpha (picograms/mL) is an inflammatory biomarker that will be meaured in a blood sample obtained the day of the study.
Contact information is provided by the study sponsor or research team.
Lorenzo Berra, MD
CONTACT
Maurizio F Cereda, MD
CONTACT
Maurizio F. Cereda, MD
Other
Imaging the Respiratory Effects of Truncal Adiposity in Acute Hypoxemic Respiratory Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07452406
Acute Hypoxemic Respiratory Failure, High-Flow Nasal Cannula Therapy
Chicago, Illinois, United States
View Trial DetailsNCT07460427
Acute Hypoxemic Respiratory Failure, Respiration Disorders
Kigali, Rwanda
View Trial DetailsNCT07463885
Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
View Trial DetailsNCT07281911
ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxemic Respiratory Failure
Barcelona, Spain
View Trial Details